EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展  

Progress on biomarkers of EB virus-related posttransplant lymphoproliferative disease

作　　者：艾亮 张盛[1] 王强[1] 李夏 成柯[1] Ai Liang;Zhang Sheng;Wang Qiang;Li Xia;Cheng Ke(Department of Transplant Surgery,the Third Xiangya Hospital,Central South University,Changsha 410013,China)

机构地区：[1]中南大学湘雅三医院移植外科,长沙410013

出　　处：《器官移植》2021年第6期767-772,共6页Organ Transplantation

基　　金：湖南省自然科学基金(2018JJ2619)。

摘　　要：移植后淋巴组织增生性疾病(PTLD)是一系列异质性淋巴增生性疾病,也是儿童实体器官移植术后的严重并发症。超过70%的PTLD与爱泼斯坦-巴尔病毒(EBV)有关,EBV相关性B细胞淋巴瘤也是儿童器官移植术后的主要恶性肿瘤。EBV相关性PTLD在儿童实体器官移植中仍然是一个棘手的问题,主要由移植术后的免疫抑制导致机体免疫功能受损所致,但具体发生机制仍不清楚。近年来,在EBV相关性PTLD的临床诊断和治疗中,开发生物标志物以实现指导诊断和个性化治疗具有极好的应用前景。本文旨在综述实体器官移植EBV相关性PTLD的发生情况及其生物标志物的研究进展,以期为临床诊疗开拓思路。Posttransplant lymphoproliferative disease(PTLD)is a series of heterogeneous lymphoproliferative diseases and a severe complication after solid organ transplantation in children.Over 70%of PTLD is associated with Epstein-Barr virus(EBV).EBV-related B-cell lymphoma is also the main malignant tumor after pediatric organ transplantation.EBV-related PTLD is still a challenge in pediatric solid organ transplantation,which is mainly caused by immune function damage induced by immune suppression after transplantation.However,the specific mechanism remains elusive.In recent years,biomarkers have been developed to guide the diagnosis and individualized treatment of EBV-related PTLD,which possesses excellent application prospect.In this article,research progresses on the incidence of EBV-related PTLD in solid organ transplantation and its biomarkers were reviewed,aiming to explore novel ideas for clinical diagnosis and treatment.

关 键 词：爱泼斯坦-巴尔病毒(EBV) 器官移植 移植后淋巴组织增生性疾病(PTLD) B细胞淋巴瘤 生物标志物 免疫抑制 病毒载量 微小核糖核酸 

分 类 号：R617[医药卫生—外科学] R373[医药卫生—临床医学]